Lecia V. Sequist

76.6k total citations · 17 hit papers
368 papers, 30.9k citations indexed

About

Lecia V. Sequist is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Lecia V. Sequist has authored 368 papers receiving a total of 30.9k indexed citations (citations by other indexed papers that have themselves been cited), including 308 papers in Pulmonary and Respiratory Medicine, 265 papers in Oncology and 80 papers in Molecular Biology. Recurrent topics in Lecia V. Sequist's work include Lung Cancer Treatments and Mutations (288 papers), Colorectal Cancer Treatments and Studies (97 papers) and Lung Cancer Research Studies (92 papers). Lecia V. Sequist is often cited by papers focused on Lung Cancer Treatments and Mutations (288 papers), Colorectal Cancer Treatments and Studies (97 papers) and Lung Cancer Research Studies (92 papers). Lecia V. Sequist collaborates with scholars based in United States, Taiwan and Canada. Lecia V. Sequist's co-authors include Daniel A. Haber, Rebecca S. Heist, Jeffrey A. Engelman, Thomas J. Lynch, Mehmet Toner, Alona Muzikansky, Shyamala Maheswaran, Daphne W. Bell, James Chih‐Hsin Yang and Justin F. Gainor and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Lecia V. Sequist

358 papers receiving 30.4k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Isolation of rare circulating tumour cells in cancer patients by microchip technology

2007 2.9k citations Lecia V. Sequist, Shyamala Maheswaran et al. profile →
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations

2013 2.5k citations Lecia V. Sequist, James Chih‐Hsin Yang et al. Journal of Clinical Oncology profile →
Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition

2013 1.9k citations Min Yu, Aditya Bardia et al. Science profile →
Lung cancer

2021 1.6k citations Lecia V. Sequist, Justin F. Gainor et al. profile →
Detection of Mutations in EGFR in Circulating Lung-Cancer Cells

2008 1.3k citations Shyamala Maheswaran, Lecia V. Sequist et al. profile →
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

2016 1.1k citations James Chih‐Hsin Yang, Lecia V. Sequist et al. profile →
Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers

2012 976 citations Alice T. Shaw, Mari Mino–Kenudson et al. profile →
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6

2015 715 citations James Chih‐Hsin Yang, Lecia V. Sequist et al. profile →
Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin

2015 712 citations Matthew J. Niederst, Lecia V. Sequist et al. profile →
Acquired resistance to TKIs in solid tumours: learning from lung cancer

2014 677 citations Lecia V. Sequist et al. profile →
First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring SomaticEGFRMutations

2008 661 citations Lecia V. Sequist, Pasi A. Jänne et al. Journal of Clinical Oncology profile →
Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: Results From the CA209-003 Study

2018 539 citations David M. Jackman, Rebecca S. Heist et al. Journal of Clinical Oncology profile →
The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies

2015 441 citations Matthew J. Niederst, Haichuan Hu et al. Clinical Cancer Research profile →
Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management

2022 303 citations Lecia V. Sequist et al. profile →
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study

2020 295 citations Lecia V. Sequist, Ji‐Youn Han et al. profile →
Sybil: A Validated Deep Learning Model to Predict Future Lung Cancer Risk From a Single Low-Dose Chest Computed Tomography

2023 114 citations Lecia V. Sequist, Florian J. Fintelmann et al. Journal of Clinical Oncology profile →
Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, MET -Amplified Non–Small Cell Lung Cancer: TATTON

2022 95 citations Ryan J. Hartmaier, Aleksandra Markovets et al. Cancer Discovery profile →

Peers

Countries citing papers authored by Lecia V. Sequist

Since Specialization

Citations

This map shows the geographic impact of Lecia V. Sequist's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lecia V. Sequist with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lecia V. Sequist more than expected).

Fields of papers citing papers by Lecia V. Sequist

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lecia V. Sequist. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lecia V. Sequist. The network helps show where Lecia V. Sequist may publish in the future.

Co-authorship network of co-authors of Lecia V. Sequist

This figure shows the co-authorship network connecting the top 25 collaborators of Lecia V. Sequist. A scholar is included among the top collaborators of Lecia V. Sequist based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lecia V. Sequist. Lecia V. Sequist is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The ASCENT Trial: a phase 2 study of induction and consolidation afatinib and chemoradiation with or without surgery in stage III EGFR-mutant NSCLC 2024 ·The Oncologist ·(unknown), (unknown), Raymond H. Mak, Michael Lanuti, Alona Muzikansky, Julia Rotow, Pasi A. Jänne, Mari Mino–Kenudson, Steven Swanson, Cameron D. Wright, David Kozono, Paul Marcoux, Zofia Piotrowska, Lecia V. Sequist, Henning Willers	8
2	OA16.04 Preliminary Results from the Female Asian Nonsmoker Screening Study (FANSS) 2023 ·Journal of Thoracic Oncology ·Elaine Shum, Wei Li, Jimmy D. Bell, Lecia V. Sequist, (unknown), Jack Goldberg, Abraham Chachoua, (unknown)	1
3	Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, MET -Amplified Non–Small Cell Lung Cancer: TATTON breakdown → 2022 ·Cancer Discovery ·Ryan J. Hartmaier, Aleksandra Markovets, Myung‐Ju Ahn, Lecia V. Sequist, Ji‐Youn Han, Byoung Chul Cho, Helena A. Yu, Sang‐We Kim, James Chih‐Hsin Yang, Jong Seok Lee, Wu‐Chou Su, Dariusz M. Kowalski, С. В. Орлов, Song Ren, Paul Frewer, Xiaoling Ou, Darren A.E. Cross, Nisha Kurian, Mireille Cantarini, Pasi A. Jänne	95
4	Modeling Resistance and Recurrence Patterns of Combined Targeted–Chemoradiotherapy Predicts Benefit of Shorter Induction Period 2020 ·Cancer Research ·David M. McClatchy, Henning Willers, Aaron N. Hata, Zofia Piotrowska, Lecia V. Sequist, Harald Paganetti, Clemens Grassberger	8
5	A Th1/IFNγ Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non–Small Cell Lung Cancer 2019 ·Clinical Cancer Research ·Benjamin Dizier, Andrea Callegaro, Muriel Debois, Brigitte Dréno, Peter Hersey, Helen Gogas, John M. Kirkwood, Johan Vansteenkiste, Lecia V. Sequist, Djordje Atanackovic, Jelle J. Goeman, Hans C. van Houwelingen, Susana Alicia Salceda, (unknown), Patrick Therasse, C. Debruyne, Bart Spiessens, Vincent Brichard, Jamila Louahed, Fernando Ulloa‐Montoya	13
6	Patient-Specific Tumor Growth Trajectories Determine Persistent and Resistant Cancer Cell Populations during Treatment with Targeted Therapies 2019 ·Cancer Research ·Clemens Grassberger, David M. McClatchy, Changran Geng, Sophia C. Kamran, Florian J. Fintelmann, Yosef E. Maruvka, Zofia Piotrowska, Henning Willers, Lecia V. Sequist, Aaron N. Hata, Harald Paganetti	24
7	EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas 2018 ·Clinical Cancer Research ·Susan E. Jorge, Antonio R. Lucena‐Araujo, Hiroyuki Yasuda, Zofia Piotrowska, Geoffrey R. Oxnard, Deepa Rangachari, Mark S. Huberman, Lecia V. Sequist, Susumu Kobayashi, Daniel B. Costa	51
8	A Digital RNA Signature of Circulating Tumor Cells Predicting Early Therapeutic Response in Localized and Metastatic Breast Cancer 2018 ·Cancer Discovery ·Tanya T. Kwan, Aditya Bardia, Laura M. Spring, Anita Giobbie‐Hurder, Mark Kalinich, Taronish D. Dubash, Tilak Sundaresan, Xin Hong, Joseph A. LiCausi, Uyen Ho, (unknown), Ben S. Wittner, Lecia V. Sequist, Ravi Kapur, David T. Miyamoto, Mehmet Toner, Daniel A. Haber, Shyamala Maheswaran	78
9	Radiation Resistance in KRAS-Mutated Lung Cancer Is Enabled by Stem-like Properties Mediated by an Osteopontin–EGFR Pathway 2017 ·Cancer Research ·(unknown), Jing Han, Lynnette Marcar, Joshua C. Black, Qi Liu, Xiangyong Li, Kshithija Nagulapalli, Lecia V. Sequist, Raymond H. Mak, Cyril H. Benes, Theodore S. Hong, Kristin Gurtner, Mechthild Krause, Michaël Baumann, Jing X. Kang, Johnathan R. Whetstine, Henning Willers	77
10	Microfluidic isolation of platelet-covered circulating tumor cells 2017 ·Lab on a Chip ·Xiaocheng Jiang, Keith H.K. Wong, Aimal H. Khankhel, (unknown), Eduardo Reátegui, Matthew J. Phillips, Xi Luo, Nicola Aceto, Fabio Fachin, Anh Hoang, Woo Seok Kim, (unknown), Lecia V. Sequist, Shyamala Maheswaran, Daniel A. Haber, Shannon L. Stott, Mehmet Toner	115
11	The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies breakdown → 2015 ·Clinical Cancer Research ·Matthew J. Niederst, Haichuan Hu, Hillary E. Mulvey, Elizabeth L. Lockerman, Angel R. Garcia, Zofia Piotrowska, Lecia V. Sequist, Jeffrey A. Engelman	441
12	Brain Tumor Cells in Circulation Are Enriched for Mesenchymal Gene Expression 2014 ·Cancer Discovery ·James P. Sullivan, Brian V. Nahed, Marissa W. Madden, (unknown), Simeon Springer, Deepak Bhere, S. Andrew, Hiroaki Wakimoto, S. Michael Rothenberg, Lecia V. Sequist, Ravi Kapur, Khalid Shah, A. John Iafrate, William T. Curry, Jay S. Loeffler, Tracy T. Batchelor, David N. Louis, Mehmet Toner, Shyamala Maheswaran, Daniel A. Haber	200
13	Variation in Mechanisms of Acquired Resistance Among EGFR-Mutant NSCLC Patients With More Than 1 Postresistant Biopsy 2014 ·International Journal of Radiation OncologyBiologyPhysics ·Zofia Piotrowska, Matthew J. Niederst, Mari Mino–Kenudson, Vicente Morales‐Oyarvide, Linnea Fulton, Elizabeth L. Lockerman, Emily Howe, Justin F. Gainor, P. Fidias, Rebecca S. Heist, Alice T. Shaw, J. A. Engelman, Lecia V. Sequist	12
14	Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations breakdown → 2013 ·Journal of Clinical Oncology ·Lecia V. Sequist, James Chih‐Hsin Yang, Nobuyuki Yamamoto, Kenneth J. O’Byrne, Vera Hirsh, Tony Mok, Sarayut Lucien Geater, С. В. Орлов, Chun‐Ming Tsai, Michael Boyer, Wu‐Chou Su, Jaafar Bennouna, Terufumi Kato, В. А. Горбунова, Ki Hyeong Lee, Riyaz Shah, Dan Massey, Victoria Zazulina, Mehdi Shahidi, Martin Schüler	2461
15	Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition breakdown → 2013 ·Science ·Min Yu, Aditya Bardia, Ben S. Wittner, Shannon L. Stott, Malgorzata E. Smas, David T. Ting, Steven J. Isakoff, Jordan C. Ciciliano, (unknown), Ajay M. Shah, Kyle Concannon, Maria Donaldson Collier, Lecia V. Sequist, Elena F. Brachtel, Dennis C. Sgroi, José Baselga, Sridhar Ramaswamy, Mehmet Toner, Daniel A. Haber, Shyamala Maheswaran	1928
16	EGFR-Activating Mutations Correlate with a Fanconi Anemia–like Cellular Phenotype That Includes PARP Inhibitor Sensitivity 2013 ·Cancer Research ·(unknown), Meng Wang, Liliana Gheorghiu, (unknown), Patricia Greninger, Kerstin Borgmann, Jeffrey Settleman, Cyril H. Benes, Lecia V. Sequist, Lee Zou, Henning Willers	35
17	Androgen Receptor Signaling in Circulating Tumor Cells as a Marker of Hormonally Responsive Prostate Cancer 2012 ·Cancer Discovery ·David T. Miyamoto, Richard J. Lee, Shannon L. Stott, David T. Ting, Ben S. Wittner, Matthew Ulman, Malgorzata E. Smas, Jenna B. Lord, Brian W. Brannigan, Julie Trautwein, Neil H. Bander, Chin‐Lee Wu, Lecia V. Sequist, Matthew R. Smith, Sridhar Ramaswamy, Mehmet Toner, Shyamala Maheswaran, Daniel A. Haber	217
18	Amplification of CRKL Induces Transformation and Epidermal Growth Factor Receptor Inhibitor Resistance in Human Non–Small Cell Lung Cancers 2011 ·Cancer Discovery ·Hiu Wing Cheung, Jinyan Du, Jesse S. Boehm, Frank He, Barbara A. Weir, Xiaoxing Wang, Mohit Butaney, Lecia V. Sequist, Biao Luo, Jeffrey A. Engelman, David E. Root, Matthew Meyerson, Todd R. Golub, Pasi A. Jänne, William C. Hahn	110
19	Phase I/II trial of the novel Hsp90 inhibitor, IPI-504, in patients with relapsed and/or refractory stage IIIB or stage IV non-small cell lung cancer stratified by EGFR mutation status 2007 ·Molecular Cancer Therapeutics ·Lecia V. Sequist, Pasi A. Jänne, John R. Walker, Jennifer Sweeney, David Grayzel, Thomas J. Lynch	14
20	Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib 2006 ·Clinical Cancer Research ·David M. Jackman, Beow Y. Yeap, Lecia V. Sequist, Neal I. Lindeman, Alison J. Holmes, Victoria A. Joshi, Daphne W. Bell, Mark S. Huberman, Balázs Halmos, Michael S. Rabin, Daniel A. Haber, Thomas J. Lynch, Matthew Meyerson, Bruce E. Johnson, Pasi A. Jänne	491

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact